Cargando…
细胞周期检测点激酶与肺癌耐药研究进展
Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105604/ https://www.ncbi.nlm.nih.gov/pubmed/33910274 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09 |
_version_ | 1783689634562179072 |
---|---|
collection | PubMed |
description | Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer. |
format | Online Article Text |
id | pubmed-8105604 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-81056042021-05-24 细胞周期检测点激酶与肺癌耐药研究进展 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death. Although great progress has been made in chemotherapy, radiotherapy and targeted therapy, the emergence of acquired drug resistance hinders the efficacy of clinical treatment. Studies have shown that tumor is a class of diseases with damaged cell cycle regulation mechanism, in which checkpoint kinase (Chk) plays a core role, Chk1 and Chk2 are very important protein kinases in the checkpoint. In recent years, it has been found that the regulation of Chk1 and Chk2 plays an important role in the clinical treatment and drug resistance mechanism of lung cancer. This article reviews the mechanism of cell cycle checkpoint kinase and drug resistance of lung cancer, and expounds the effective therapeutic targets and methods of lung cancer. 中国肺癌杂志编辑部 2021-04-20 /pmc/articles/PMC8105604/ /pubmed/33910274 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09 Text en 版权所有©《中国肺癌杂志》编辑部2021 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | 综述 细胞周期检测点激酶与肺癌耐药研究进展 |
title | 细胞周期检测点激酶与肺癌耐药研究进展 |
title_full | 细胞周期检测点激酶与肺癌耐药研究进展 |
title_fullStr | 细胞周期检测点激酶与肺癌耐药研究进展 |
title_full_unstemmed | 细胞周期检测点激酶与肺癌耐药研究进展 |
title_short | 细胞周期检测点激酶与肺癌耐药研究进展 |
title_sort | 细胞周期检测点激酶与肺癌耐药研究进展 |
topic | 综述 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105604/ https://www.ncbi.nlm.nih.gov/pubmed/33910274 http://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.09 |
work_keys_str_mv | AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn AT xìbāozhōuqījiǎncèdiǎnjīméiyǔfèiáinàiyàoyánjiūjìnzhǎn |